# Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

> **NCT03990493** · PHASE1 · UNKNOWN · sponsor: **PrimeVax Immuno-Oncology Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** Dengue Virus-1 #45AZ5 (PV-001-DV)
- **BIOLOGICAL:** Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)

## Key facts

- **NCT ID:** NCT03990493
- **Lead sponsor:** PrimeVax Immuno-Oncology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03990493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03990493, "Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03990493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*